EA201992858A1 - Соединения и композиции для индуцирования хондрогенеза - Google Patents

Соединения и композиции для индуцирования хондрогенеза

Info

Publication number
EA201992858A1
EA201992858A1 EA201992858A EA201992858A EA201992858A1 EA 201992858 A1 EA201992858 A1 EA 201992858A1 EA 201992858 A EA201992858 A EA 201992858A EA 201992858 A EA201992858 A EA 201992858A EA 201992858 A1 EA201992858 A1 EA 201992858A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
chondrogenesis
induction
compositions
present
Prior art date
Application number
EA201992858A
Other languages
English (en)
Inventor
Ха-Соон Чои
Цзицин Цзян
Джеймс Пол Лэджинесс
Бао Нгуйен
Ханк Майкл Джеймс Петрасси
Чжичэнь Ван
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201992858A1 publication Critical patent/EA201992858A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Abstract

В настоящем изобретении предложено соединение формулы (I)или его фармацевтически приемлемая соль, таутомер или стереоизомер, где переменные принимают значения, определенные в настоящем документе. Настоящее изобретение также относится к фармацевтическим композициям, содержащим такие соединения, и способам применения таких соединений для лечения повреждения сустава или травмы сустава у млекопитающего, для индуцирования выработки гиалинового хряща или для индуцирования дифференцировки хондрогенных клеток-предшественников в зрелые хондроциты.
EA201992858A 2017-06-09 2018-06-07 Соединения и композиции для индуцирования хондрогенеза EA201992858A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (1)

Publication Number Publication Date
EA201992858A1 true EA201992858A1 (ru) 2020-04-02

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992858A EA201992858A1 (ru) 2017-06-09 2018-06-07 Соединения и композиции для индуцирования хондрогенеза

Country Status (35)

Country Link
US (3) US11091499B2 (ru)
EP (3) EP3915994B9 (ru)
JP (2) JP7229945B2 (ru)
KR (1) KR102656524B1 (ru)
CN (1) CN110719913B (ru)
AR (1) AR113227A1 (ru)
AU (1) AU2018279306C1 (ru)
BR (1) BR112019025866A2 (ru)
CA (1) CA3063985A1 (ru)
CL (1) CL2019003564A1 (ru)
CO (1) CO2019013706A2 (ru)
CR (1) CR20190551A (ru)
CU (1) CU24577B1 (ru)
DK (1) DK3915994T3 (ru)
DO (1) DOP2019000305A (ru)
EA (1) EA201992858A1 (ru)
EC (1) ECSP19086712A (ru)
FI (1) FI3915994T3 (ru)
HR (1) HRP20240155T1 (ru)
IL (2) IL300755A (ru)
JO (1) JOP20190282A1 (ru)
LT (1) LT3915994T (ru)
MA (2) MA57022B1 (ru)
MX (1) MX2019014757A (ru)
NZ (1) NZ759434A (ru)
PE (1) PE20200403A1 (ru)
PH (1) PH12019502764A1 (ru)
PT (1) PT3915994T (ru)
RS (1) RS65161B1 (ru)
SA (1) SA519410729B1 (ru)
SI (1) SI3915994T1 (ru)
TW (1) TWI782036B (ru)
UY (1) UY37759A (ru)
WO (1) WO2018225009A1 (ru)
ZA (1) ZA201907358B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
WO2020115683A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JP7427665B2 (ja) * 2018-12-06 2024-02-05 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための６－ヒドロキシ－８－オキサトリシクロ［３．２．１．０２，４］オクタン－２－カルボキサミド誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272640T1 (de) * 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2757480A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
CA2767826C (en) 2009-07-14 2015-11-24 The Scripps Research Institute Mesenchymal stem cell differentiation using aniopoietin-like-3
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
KR102283996B1 (ko) * 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
AP2016009502A0 (en) 2014-05-13 2016-10-31 Novartis Ag Compounds and compositions for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
JP2020522550A (ja) 2020-07-30
HRP20240155T1 (hr) 2024-04-12
DK3915994T3 (da) 2024-02-19
MA50547A (fr) 2020-09-16
WO2018225009A1 (en) 2018-12-13
AU2018279306C1 (en) 2021-01-14
EP3634967A1 (en) 2020-04-15
RU2019144107A3 (ru) 2021-07-30
PT3915994T (pt) 2024-02-15
UY37759A (es) 2019-01-31
CU24577B1 (es) 2022-02-04
JOP20190282A1 (ar) 2019-12-05
EP3915994A1 (en) 2021-12-01
TWI782036B (zh) 2022-11-01
US20230365580A1 (en) 2023-11-16
EP4299123A3 (en) 2024-04-03
JP7432778B2 (ja) 2024-02-16
AR113227A1 (es) 2020-02-19
US20210079010A1 (en) 2021-03-18
AU2018279306B2 (en) 2020-07-09
JP2023062064A (ja) 2023-05-02
JP7229945B2 (ja) 2023-02-28
NZ759434A (en) 2024-01-26
CA3063985A1 (en) 2018-12-13
AU2018279306A1 (en) 2019-12-05
IL271154A (en) 2020-01-30
RS65161B1 (sr) 2024-02-29
BR112019025866A2 (pt) 2020-07-14
PH12019502764A1 (en) 2020-07-13
KR20200013046A (ko) 2020-02-05
CN110719913B (zh) 2022-10-28
CR20190551A (es) 2020-01-28
CL2019003564A1 (es) 2020-06-19
CN110719913A (zh) 2020-01-21
RU2019144107A (ru) 2021-07-09
CO2019013706A2 (es) 2020-04-01
IL300755A (en) 2023-04-01
FI3915994T3 (fi) 2024-02-14
PE20200403A1 (es) 2020-02-26
TW201902900A (zh) 2019-01-16
CU20190098A7 (es) 2020-10-20
IL271154B2 (en) 2023-07-01
US11753416B2 (en) 2023-09-12
EP4299123A2 (en) 2024-01-03
ECSP19086712A (es) 2019-12-27
LT3915994T (lt) 2024-02-26
EP3915994B9 (en) 2024-02-28
MX2019014757A (es) 2020-02-12
IL271154B1 (en) 2023-03-01
SI3915994T1 (sl) 2024-03-29
ZA201907358B (en) 2022-04-28
US11091499B2 (en) 2021-08-17
MA57022B1 (fr) 2024-02-29
EP3915994B1 (en) 2023-11-22
US20210347784A1 (en) 2021-11-11
KR102656524B1 (ko) 2024-04-12
DOP2019000305A (es) 2019-01-15
SA519410729B1 (ar) 2022-07-03

Similar Documents

Publication Publication Date Title
PH12016502005B1 (en) Compounds and compositions for inducing chondrogenesis
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
IN2014MN02106A (ru)
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
UA110310C2 (ru) Соединения n-арил триазола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
IN2014DN09347A (ru)
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201490031A1 (ru) Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth
MD20160111A2 (ru) Бигетероциклические производные связанные с циклоалкилом
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists